238 related articles for article (PubMed ID: 20158876)
1. Differences in the transactivation domains of p53 family members: a computational study.
Mavinahalli JN; Madhumalar A; Beuerman RW; Lane DP; Verma C
BMC Genomics; 2010 Feb; 11 Suppl 1(Suppl 1):S5. PubMed ID: 20158876
[TBL] [Abstract][Full Text] [Related]
2. Interaction of regulators Mdm2 and Mdmx with transcription factors p53, p63 and p73.
Zdzalik M; Pustelny K; Kedracka-Krok S; Huben K; Pecak A; Wladyka B; Jankowski S; Dubin A; Potempa J; Dubin G
Cell Cycle; 2010 Nov; 9(22):4584-91. PubMed ID: 21088494
[TBL] [Abstract][Full Text] [Related]
3. Molecular basis of the interactions between the p73 N terminus and p300: effects on transactivation and modulation by phosphorylation.
Burge S; Teufel DP; Townsley FM; Freund SM; Bycroft M; Fersht AR
Proc Natl Acad Sci U S A; 2009 Mar; 106(9):3142-7. PubMed ID: 19218448
[TBL] [Abstract][Full Text] [Related]
4. Conformational stability and activity of p73 require a second helix in the tetramerization domain.
Coutandin D; Löhr F; Niesen FH; Ikeya T; Weber TA; Schäfer B; Zielonka EM; Bullock AN; Yang A; Güntert P; Knapp S; McKeon F; Ou HD; Dötsch V
Cell Death Differ; 2009 Dec; 16(12):1582-9. PubMed ID: 19763140
[TBL] [Abstract][Full Text] [Related]
5. The p73 DNA binding domain displays enhanced stability relative to its homologue, the tumor suppressor p53, and exhibits cooperative DNA binding.
Patel S; Bui TT; Drake AF; Fraternali F; Nikolova PV
Biochemistry; 2008 Mar; 47(10):3235-44. PubMed ID: 18260640
[TBL] [Abstract][Full Text] [Related]
6. The functional domains in p53 family proteins exhibit both common and distinct properties.
Harms KL; Chen X
Cell Death Differ; 2006 Jun; 13(6):890-7. PubMed ID: 16543939
[No Abstract] [Full Text] [Related]
7. Regulation of the Activity in the p53 Family Depends on the Organization of the Transactivation Domain.
Krauskopf K; Gebel J; Kazemi S; Tuppi M; Löhr F; Schäfer B; Koch J; Güntert P; Dötsch V; Kehrloesser S
Structure; 2018 Aug; 26(8):1091-1100.e4. PubMed ID: 30099987
[TBL] [Abstract][Full Text] [Related]
8. Structural convergence of unstructured p53 family transactivation domains in MDM2 recognition.
Shin JS; Ha JH; Lee DH; Ryu KS; Bae KH; Park BC; Park SG; Yi GS; Chi SW
Cell Cycle; 2015; 14(4):533-43. PubMed ID: 25591003
[TBL] [Abstract][Full Text] [Related]
9. P53 and p73 differ in their ability to inhibit glucocorticoid receptor (GR) transcriptional activity.
Zhang L; Nie L; Maki CG
Mol Cancer; 2006 Dec; 5():68. PubMed ID: 17150106
[TBL] [Abstract][Full Text] [Related]
10. Structural evolution of p53, p63, and p73: implication for heterotetramer formation.
Joerger AC; Rajagopalan S; Natan E; Veprintsev DB; Robinson CV; Fersht AR
Proc Natl Acad Sci U S A; 2009 Oct; 106(42):17705-10. PubMed ID: 19815500
[TBL] [Abstract][Full Text] [Related]
11. Dimerization of the core domain of the p53 family: a computational study.
Madhumalar A; Jun LH; Lane DP; Verma CS
Cell Cycle; 2009 Jan; 8(1):137-48. PubMed ID: 19106606
[TBL] [Abstract][Full Text] [Related]
12. Functional interplay between MDM2, p63/p73 and mutant p53.
Stindt MH; Muller PA; Ludwig RL; Kehrloesser S; Dötsch V; Vousden KH
Oncogene; 2015 Aug; 34(33):4300-10. PubMed ID: 25417702
[TBL] [Abstract][Full Text] [Related]
13. Molecular basis of S100 proteins interacting with the p53 homologs p63 and p73.
van Dieck J; Brandt T; Teufel DP; Veprintsev DB; Joerger AC; Fersht AR
Oncogene; 2010 Apr; 29(14):2024-35. PubMed ID: 20140014
[TBL] [Abstract][Full Text] [Related]
14. Transactivation specificity is conserved among p53 family proteins and depends on a response element sequence code.
Ciribilli Y; Monti P; Bisio A; Nguyen HT; Ethayathulla AS; Ramos A; Foggetti G; Menichini P; Menendez D; Resnick MA; Viadiu H; Fronza G; Inga A
Nucleic Acids Res; 2013 Oct; 41(18):8637-53. PubMed ID: 23892287
[TBL] [Abstract][Full Text] [Related]
15. Structural investigations of the p53/p73 homologs from the tunicate species Ciona intestinalis reveal the sequence requirements for the formation of a tetramerization domain.
Heering J; Jonker HR; Löhr F; Schwalbe H; Dötsch V
Protein Sci; 2016 Feb; 25(2):410-22. PubMed ID: 26473758
[TBL] [Abstract][Full Text] [Related]
16. C-terminal diversity within the p53 family accounts for differences in DNA binding and transcriptional activity.
Sauer M; Bretz AC; Beinoraviciute-Kellner R; Beitzinger M; Burek C; Rosenwald A; Harms GS; Stiewe T
Nucleic Acids Res; 2008 Apr; 36(6):1900-12. PubMed ID: 18267967
[TBL] [Abstract][Full Text] [Related]
17. Impact of cadmium, cobalt and nickel on sequence-specific DNA binding of p63 and p73 in vitro and in cells.
Adámik M; Bažantová P; Navrátilová L; Polášková A; Pečinka P; Holaňová L; Tichý V; Brázdová M
Biochem Biophys Res Commun; 2015 Jan; 456(1):29-34. PubMed ID: 25446071
[TBL] [Abstract][Full Text] [Related]
18. MDM2 and MDMX can interact differently with ARF and members of the p53 family.
Wang X; Arooz T; Siu WY; Chiu CH; Lau A; Yamashita K; Poon RY
FEBS Lett; 2001 Feb; 490(3):202-8. PubMed ID: 11223036
[TBL] [Abstract][Full Text] [Related]
19. Design of a novel MDM2 binding peptide based on the p53 family.
Madhumalar A; Lee HJ; Brown CJ; Lane D; Verma C
Cell Cycle; 2009 Sep; 8(17):2828-36. PubMed ID: 19713735
[TBL] [Abstract][Full Text] [Related]
20. Protein kinase C-dependent phosphorylation regulates the cell cycle-inhibitory function of the p73 carboxy terminus transactivation domain.
Nyman U; Vlachos P; Cascante A; Hermanson O; Zhivotovsky B; Joseph B
Mol Cell Biol; 2009 Apr; 29(7):1814-25. PubMed ID: 19158275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
